Index falls as earnings results weigh; pound above $1.33, Bodycote soars
NEWPORT BEACH, Calif. - Evolus, Inc. (NASDAQ: EOLS) has announced the publication of a study in the Aesthetic Surgery Journal that demonstrates the effectiveness of its Evolysse™ Form and Evolysse™ Smooth products, which are part of the company’s portfolio of injectable hyaluronic acid (HA) gels used for the cosmetic treatment of facial wrinkles and folds.
The study, which was a randomized, controlled, double-blind trial involving 140 patients over a 12-month period, showed that both Evolysse™ Form and Evolysse™ Smooth met the primary endpoint of non-inferiority to Restylane®-L, a leading HA gel. Moreover, the products demonstrated statistical superiority to Restylane®-L, with Evolysse™ Form showing significant differences at all measured timepoints and Evolysse™ Smooth at 6 and 9 months.
Patients reported over 80% satisfaction with the treatments, indicating they would choose to undergo the procedure again and recommend it to others. The safety profile of Evolysse™ products was comparable to the control, with no serious adverse events related to treatment reported.
Dr. Rui Avelar, Chief Medical Officer and Head of R&D at Evolus, highlighted the efficiency of Evolysse™ products, noting that Evolysse™ Form used the same amount of product as the control and achieved more correction, while Evolysse™ Smooth used 20% less product and still delivered more correction at significant levels.
Evolus has also received EU Medical Device Regulation (MDR) approval for four HA gels under the brand name Estyme®, and is preparing for a broader European launch slated for the second half of 2025, aiming to expand its global presence in the dermal filler market.
This study supports the company’s mission to redefine the aesthetic injectable market and strengthen its position as a leader in performance beauty. Information about the study is based on a press release statement from Evolus, Inc. Wall Street analysts maintain a strong buy consensus on the stock, with price targets suggesting significant upside potential. For detailed financial analysis and additional insights, including 6 key ProTips about Evolus’s financial health and growth prospects, visit InvestingPro, where you can access comprehensive research reports and expert analysis.
In other recent news, Evolus Inc. reported its Q1 2025 earnings, revealing a larger-than-expected loss with an EPS of -$0.30, which missed the forecast of -$0.09. Despite this, the company’s revenue grew by 15.5% year-over-year to $68.5 million, although it fell short of the $72.51 million projection. The company reaffirmed its full-year revenue guidance of $345-$355 million and is targeting $700 million in net revenue by 2028. Evolus recently launched a new product, Evolisse, which is expected to contribute 8-10% of total revenue in 2025. Analysts have taken note of Evolus’ strategic initiatives, with firms like Stifel and Leerink Partners closely monitoring the company’s market performance and product launches. The company continues to face challenges such as market slowdown, tariff exposure, and competitive pressure, but remains confident in its growth trajectory. Evolus’ CEO highlighted the successful start to the year and emphasized the potential of Evolisse as a complement to their existing product, Jeuveau.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.